Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FTC (emtricitabine, Emtriva)

    Project Inform Perspective
    |December 31, 2003
    PubMed
    Summary
    This summary is machine-generated.

    The FDA approved emtricitabine (FTC) in 2003 as a combination therapy for adults with HIV. FTC is a nucleoside analog reverse transcriptase inhibitor (NRTI) used with other anti-HIV medications.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Everything antiretroviral: 5th IAS conference, Cape Town, South Africa.

    Project Inform perspective·2012
    Same journal

    Well implemented, President Obama's national HIV/AIDS strategy is precisely what is needed to further control HIV/AIDS.

    Project Inform perspective·2011
    Same journal

    Finding health care; preparing for the future.

    Project Inform perspective·2011
    Same journal

    Protecting people with HIV in the California budget.

    Project Inform perspective·2010
    Same journal

    Current drugs in clinical study.

    Project Inform perspective·2010
    Same journal

    HIV treatment information.

    Project Inform perspective·2010
    See all related articles

    Area of Science:

    • Antiviral drug development
    • HIV/AIDS therapeutics
    • Nucleoside analog reverse transcriptase inhibitors (NRTIs)

    Background:

    • Emtricitabine (FTC) is an NRTI medication.
    • FTC was approved by the FDA in July 2003.
    • It is indicated for adult use in combination with other anti-HIV drugs.

    Discussion:

    • FTC's mechanism of action involves inhibiting HIV replication.
    • Its approval expanded treatment options for HIV/AIDS.
    • Combination therapy is a cornerstone of effective HIV management.

    Key Insights:

    • FTC (emtricitabine) is an NRTI.
    • FDA approval in 2003 for combination HIV therapy.
    • Classified alongside other NRTIs like 3TC, abacavir, and AZT.

    Outlook:

    • Continued research into NRTI efficacy and resistance.
    • Potential for FTC in novel combination regimens.
    • Long-term management strategies for HIV infection.